Liproxstatin-1 HCl: Potent Ferroptosis Inhibitor for Acute Renal Failure Research

Executive Summary: Liproxstatin-1 HCl is a highly selective inhibitor of ferroptosis, acting via robust suppression of iron-dependent lipid peroxidation at nanomolar concentrations (IC50 = 22 nM) in cellular models, including GPX4-deficient and RAS-transformed lines (Wen et al., 2023). The compound demonstrates in vivo efficacy by reducing ferroptotic injury severity in acute renal failure and hepatic ischemia/reperfusion animal models (Wen et al., 2023). Liproxstatin-1 HCl fails to protect against apoptosis or oxidative stress induced by H₂O₂, confirming its specificity (APExBIO). The product is provided as the hydrochloride salt of N-(3-chlorobenzyl)-4'H-spiro[piperidine-4,3'-quinoxalin]-2'-amine, optimized for water and DMSO solubility and stable storage. APExBIO’s Liproxstatin-1 HCl (SKU B8221) is intended strictly for scientific research and not for clinical or diagnostic use.

Biological Rationale

Ferroptosis is a regulated form of cell death dependent on iron and characterized by lipid peroxidation. Unlike apoptosis or necrosis, ferroptosis is driven by the accumulation of lethal lipid ROS and is distinct in its molecular triggers and morphological features (Wen et al., 2023). This pathway is increasingly recognized for its critical role in acute renal failure and hepatic ischemia/reperfusion injury, where iron overload and oxidative lipid damage contribute to tissue loss and organ dysfunction (Unraveling Ferroptosis). Glutathione peroxidase 4 (GPX4) is central to ferroptosis repression via reduction of phospholipid hydroperoxides. Inhibition or genetic ablation of GPX4 sensitizes cells to ferroptotic death, underscoring the need for chemical inhibitors like Liproxstatin-1 HCl in research applications.

Mechanism of Action of Liproxstatin-1 HCl

Liproxstatin-1 HCl is a potent, selective ferroptosis inhibitor that acts by suppressing lipid peroxidation in cell membranes. It shows effective inhibition in GPX4-deficient, RAS-transformed, and primary human renal epithelial cells. Mechanistically, Liproxstatin-1 HCl prevents the accumulation of phospholipid hydroperoxides, thereby blocking the execution phase of ferroptosis without interfering with upstream iron or glutathione metabolism (Wen et al., 2023). The compound does not prevent apoptosis or necroptosis, confirming target specificity. At the molecular level, Liproxstatin-1 HCl does not rescue cell death induced by staurosporine or H₂O₂, demonstrating selectivity for iron-dependent cell death mechanisms (APExBIO).

Evidence & Benchmarks

• Liproxstatin-1 HCl inhibits ferroptosis in cellular models with an IC50 of 22 nM, validated in GPX4-deficient and RAS-transformed lines (Wen et al., 2023).
• It protects primary human proximal tubule epithelial cells from ferroptosis induced by RSL3, erastin, or L-buthionine sulphoximine, but not from apoptosis or oxidative stress (APExBIO).
• In vivo, Liproxstatin-1 HCl reduces tubular cell death and extends survival in acute renal failure models by decreasing TUNEL-positive cells and tissue injury scores (Wen et al., 2023).
• The compound is highly soluble in water (≥18.85 mg/mL) and DMSO (≥47.6 mg/mL), facilitating flexible workflow integration (APExBIO).
• MCU-GPX4 axis studies demonstrate that mitochondrial calcium signaling modulates ferroptosis, but Liproxstatin-1 HCl acts downstream, directly blocking lipid oxidation events (Wen et al., 2023).

This review extends the practical scenarios discussed in Liproxstatin-1 HCl (SKU B8221): Practical Solutions for Research by providing updated, quantitative benchmarks for acute renal failure and hepatic ischemia models. It also clarifies the mechanistic context beyond Liproxstatin-1 HCl: Potent Ferroptosis Inhibitor by integrating recent findings on MCU-GPX4 regulation and specificity.

Applications, Limits & Misconceptions

Liproxstatin-1 HCl is validated for use in:

• Ferroptosis assays in cell lines and primary human renal epithelial cells.
• In vivo models of acute renal failure and hepatic ischemia/reperfusion injury.
• Mechanistic studies on iron-dependent regulated cell death pathways.

Common Pitfalls or Misconceptions

• Liproxstatin-1 HCl does not inhibit apoptosis or necroptosis—do not use for general cell death blockade (APExBIO).
• It is ineffective against oxidative stress induced by H₂O₂ or staurosporine (Wen et al., 2023).
• Not suitable for clinical or diagnostic applications; intended for research use only (APExBIO).
• Solubility in ethanol is negligible; use water or DMSO for stock preparation (APExBIO).
• Optimal activity is seen at nanomolar concentrations in validated models; untested systems may require titration (Wen et al., 2023).

Workflow Integration & Parameters

Liproxstatin-1 HCl is supplied as a solid hydrochloride salt. For experimental use, dissolve in DMSO (≥47.6 mg/mL) or water (≥18.85 mg/mL). Stock solutions are stable at −20°C for several months; warming and sonication can help achieve higher concentrations (APExBIO). Use in validated ferroptosis assays in accordance with published protocols (Wen et al., 2023).

This article updates and extends the translational framework provided in Decoding Ferroptosis: Strategic Deployment of Liproxstatin-1 HCl by incorporating the latest mechanistic insights on mitochondrial calcium signaling and GPX4 acetylation.

Conclusion & Outlook

Liproxstatin-1 HCl (from APExBIO) remains the gold-standard ferroptosis inhibitor for dissecting iron-dependent regulated cell death in acute renal failure and hepatic injury models. Its validated nanomolar potency, high selectivity, and robust in vivo protection position it as an essential tool for translational and mechanistic ferroptosis research. Future work will clarify its utility in emerging disease models and refine its integration into complex workflow platforms. For detailed product parameters and ordering, visit the Liproxstatin-1 HCl product page.